Immunic, inc. announces completion of enrollment of its phase 2 caldose-1 trial of imu-838 in moderate-to-severe ulcerative colitis

New york, oct. 28, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the final patient has been enrolled and randomized in its phase 2 caldose-1 trial of lead asset, imu-838, the company's selective oral dhodh inhibitor, in patients with moderate-to-severe ulcerative colitis (uc). top-line data for the induction phase is expected to be available in the second quarter of 2022.
IMUX Ratings Summary
IMUX Quant Ranking